Skip to content
BioAlmanacPeptide reference
Menu

Comparison

CJC-1295 vs sermorelin: half-life and schedule

CJC-1295 and sermorelin are GHRH analogues acting on the same receptor, and how long each survives in the body is the whole of the difference. It sets both the schedule and the shape of what comes out.

Both copy growth-hormone-releasing hormone and both act on the same receptor. The difference is stability: sermorelin is cleared in minutes, CJC-1295 was engineered to resist the enzyme that does the clearing.

The pair is searched in both orders. Sermorelin vs CJC-1295 and CJC-1295 vs sermorelin are the same question, and this page is the answer to either — the URL keeps the older ordering, which is the only thing that differs.

That produces genuinely different behaviour. A very short-acting analogue gives a brief pulse close to the natural shape. A longer-acting one holds the baseline up for longer, which is either the point or the problem depending on which argument you believe.

One naming trap to flag. CJC-1295 with DAC and CJC-1295 without it are different molecules with very different half-lives and schedules, and the unqualified name gets used for both.

CJC-1295 vs sermorelin: half-life and schedule compared row by row
AttributeSermorelinCJC-1295
ReceptorGHRHGHRH
Evidence levelApproved elsewhereEarly human
Half-lifeMinutesAbout 30 minutes without DAC; around a week with it
Dosing frequencyOnce daily, usually at nightOnce daily without DAC; weekly with it
Pulse shapeBrief, close to naturalLonger elevation

Things worth knowing

  • Buy the wrong CJC-1295 and your schedule matches nothing written about it. Check whether a vendor's product carries DAC before you follow any protocol you have read.
  • A closer-to-natural pulse is a mechanistic argument, not a measured outcome. No study in healthy adults has compared the two on anything you would actually notice.
  • Both are usually paired with a ghrelin-receptor secretagogue rather than run alone.

Full profile

Sermorelin

The original GHRH analogue, and the only one here that once held FDA approval, withdrawn for commercial reasons and not for safety.

Full profile

CJC-1295

A GHRH analogue that raises growth hormone by amplifying the body's own release signal. Sold in two forms whose durations differ by two orders of magnitude.

Related

Another comparisonCJC-1295 vs ipamorelinThe most compared pair in this category, and the comparison is slightly wrong-headed. They act on different receptors and are usually run together rather than chosen between.Another comparisonTesamorelin vs CJC-1295Two GHRH analogues acting on the same receptor, separated by the largest evidence gap on this site. One completed a phase 3 programme and holds an approval; the other has neither.

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice.

Next

Where to take this